We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Analysis of DNA Damage Now Possible

By LabMedica International staff writers
Posted on 03 Jun 2010
New DNA analysis technology offers a new way to test potential cancer drugs and to determine the effects of environmental toxins.

DNA in living organisms is under constant siege from a variety of damaging agents. More...
Damage to DNA and the ability of cells to repair that damage has wide health implications, from aging and heritable diseases to cancer. Unfortunately, the tools used to study DNA damage are quite limited, but researchers have developed a new tool for rapid DNA damage analysis that has the potential to make an impact on human health.

The researchers, led by Dr. Bevin Engelward, Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) associate professor of biological engineering, and Dr. Sangeeta Bhatia, professor in the Harvard-MIT Division of Health Sciences and Technology and MIT's department of electrical engineering and computer science, have produced a completely revamped version of a 30-year-old lab test known as the comet assay. This new technique combines the versatility and sensitivity of the comet assay for DNA damage analysis with a robust high-capacity platform, which could make DNA damage analysis routine across a variety of applications, ranging from epidemiology to drug screening.

Dr. Engelward, Dr. Bhatia, postdoctoral fellow David Wood and graduate student David Weingeist described the technique in an article that was published in the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) the week of May 3, 2010. The technology could offer a new approach for epidemiologists to detect deadly environmental exposures long before they cause cancer, for clinicians to provide better cancer treatment, and for researchers in the pharmaceutical industry to identify new drugs and screen out hazardous drugs.

The comet assay is based on the idea that during gel electrophoresis, a typically used lab test in which an electric field is applied to DNA placed on a polymer gel, damaged DNA moves farther across the gel than undamaged DNA. The result is a "comet” made of DNA, which looks extraordinarily like its astronomic namesake. The assay is both sensitive and versatile, but it is also time-consuming and tedious. It requires at least one microscope slide for every experimental condition, which means that researchers need to handle dozens of slides just to do a few experimental conditions. Moreover, the readout is manual, meaning researchers have to spend hours staring into a microscope and selecting cells for analysis. The investigator's goal was to harness the strengths of the comet assay while overcoming its limitations in throughput and labor.

Using a micropatterning technique developed by the MIT scientists, the research team imprinted a grid of tiny wells the size of a single cell on a DNA electrophoresis gel. Cells in the array can be individually "addressed,” which allows fully automated readout and replaces the time-consuming manual analysis. They also put their microscopic cell array into a 96-well plate so that many cell types, drugs, or other conditions can be assayed simultaneously. This setup allows dozens of experimental conditions to be tested on just one slide, and it enables slides to be automatically analyzed using custom-designed imaging software.

The team is using knockout cell lines to determine which genetic deficiencies are detectable with their platform and to determine better the molecular mechanisms of DNA repair. They are also optimizing their system for human samples in order to study the DNA damaging effects of the environment. Ultimately, they hope that the CometChip will be commercialized and made available worldwide. This technology was designed not only to enable high throughput screening, but also to be compatible with basic laboratory equipment so that virtually any laboratory can use it.

Related Links:
Massachusetts Institute of Technology



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.